HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Francis J Giles Selected Research

ridaforolimus

8/2009Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.
4/2009Targeting the mTOR pathway using deforolimus in cancer therapy.
5/2008A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
11/2005Mammalian target of rapamycin as a therapeutic target in leukemia.
2/2004Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Francis J Giles Research Topics

Disease

104Neoplasms (Cancer)
11/2023 - 06/2002
51Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2016 - 06/2002
48BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
11/2023 - 03/2002
33Leukemia
10/2015 - 01/2002
28Hematologic Neoplasms (Hematological Malignancy)
11/2023 - 05/2002
27Myelodysplastic Syndromes (Myelodysplastic Syndrome)
05/2015 - 06/2002
18Philadelphia Chromosome
01/2020 - 04/2002
14B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
02/2017 - 08/2002
12Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
12/2015 - 07/2002
8Fatigue
01/2022 - 01/2003
7Lymphoma (Lymphomas)
06/2019 - 12/2003
7Multiple Myeloma
07/2012 - 05/2002
6Primary Myelofibrosis (Myelosclerosis)
08/2019 - 04/2003
6Lung Neoplasms (Lung Cancer)
03/2018 - 03/2009
6Pain (Aches)
09/2011 - 08/2002
6Myeloid Leukemia (Leukemia, Myelocytic)
11/2010 - 06/2002
5Neoplasm Metastasis (Metastasis)
01/2022 - 03/2012
5Melanoma (Melanoma, Malignant)
01/2022 - 12/2015
5Nausea
01/2020 - 09/2003
5Breast Neoplasms (Breast Cancer)
04/2018 - 02/2011
5Acute Promyelocytic Leukemia
02/2013 - 06/2002
5Thrombocytopenia (Thrombopenia)
05/2011 - 09/2002
5Blast Crisis (Blast Phase)
03/2009 - 05/2002
4Colorectal Neoplasms (Colorectal Cancer)
06/2023 - 08/2017
4Glioblastoma (Glioblastoma Multiforme)
01/2022 - 12/2015
4Mucositis
12/2019 - 06/2002
4Prostatic Neoplasms (Prostate Cancer)
11/2019 - 09/2014
4Systemic Mastocytosis
11/2015 - 10/2006
4Anemia
08/2014 - 04/2002
4Infections
08/2014 - 03/2003
4Diarrhea
08/2014 - 03/2003
4Exanthema (Rash)
10/2010 - 03/2003
4Myeloproliferative Disorders (Myeloproliferative Disorder)
02/2008 - 04/2003
4Pathologic Complete Response
06/2004 - 06/2002
4Stomatitis
06/2004 - 08/2002
3Carcinogenesis
12/2022 - 12/2003
3Glioma (Gliomas)
01/2022 - 05/2016
3Pancreatic Neoplasms (Pancreatic Cancer)
07/2021 - 06/2009
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2019 - 01/2016
3Triple Negative Breast Neoplasms
04/2018 - 01/2014
3Renal Cell Carcinoma (Grawitz Tumor)
01/2016 - 01/2010

Drug/Important Bio-Agent (IBA)

27Imatinib Mesylate (Gleevec)FDA Link
10/2015 - 05/2002
21Cytarabine (Cytosar-U)FDA LinkGeneric
02/2013 - 04/2002
18Proteins (Proteins, Gene)FDA Link
02/2023 - 07/2002
17Phosphotransferases (Kinase)IBA
11/2019 - 07/2004
15Tyrosine Kinase InhibitorsIBA
01/2020 - 09/2003
13Glycogen Synthase (Synthase I)IBA
11/2023 - 01/2017
12nilotinibFDA Link
01/2021 - 04/2009
11Immune Checkpoint InhibitorsIBA
06/2023 - 01/2016
11Gemtuzumab (Mylotarg)FDA Link
05/2007 - 06/2002
10Biomarkers (Surrogate Marker)IBA
01/2019 - 12/2003
10NucleosidesIBA
01/2008 - 01/2002
10fludarabineIBA
01/2008 - 04/2002
10Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2007 - 03/2002
9Monoclonal AntibodiesIBA
01/2017 - 05/2002
9Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric
02/2013 - 06/2002
9bcr-abl Fusion ProteinsIBA
03/2011 - 07/2002
7Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA
12/2022 - 05/2016
7TOR Serine-Threonine KinasesIBA
04/2015 - 02/2004
7Interferon-alpha (Interferon Alfa)IBA
04/2009 - 04/2002
7troxacitabineIBA
01/2007 - 02/2002
6Messenger RNA (mRNA)IBA
01/2021 - 11/2003
6Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2011 - 08/2003
6EverolimusFDA Link
08/2009 - 02/2004
5Glycogen Synthase Kinase 3IBA
06/2023 - 01/2017
5GemcitabineFDA Link
12/2019 - 08/2002
5Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2019 - 06/2002
5AntigensIBA
01/2018 - 11/2003
5VorinostatFDA Link
08/2014 - 07/2007
5Daunorubicin (Cerubidine)FDA LinkGeneric
02/2013 - 05/2002
5temsirolimusFDA Link
01/2010 - 02/2004
5ridaforolimusIBA
08/2009 - 02/2004
5Sirolimus (Rapamycin)FDA Link
08/2009 - 02/2004
5Rituximab (Mabthera)FDA Link
04/2006 - 04/2003
4CytokinesIBA
02/2023 - 06/2002
4AntibodiesIBA
01/2018 - 09/2004
4DNA (Deoxyribonucleic Acid)IBA
11/2016 - 12/2003
4EnzymesIBA
05/2015 - 11/2002
4Histone Deacetylase InhibitorsIBA
08/2014 - 07/2007
4Ribonucleotide Reductases (Ribonucleotide Reductase)IBA
01/2008 - 08/2002
43-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine)IBA
01/2008 - 08/2002
4DecitabineFDA Link
12/2005 - 08/2003
4Alemtuzumab (Campath)FDA Link
09/2004 - 05/2003
4Topotecan (Hycamtin)FDA LinkGeneric
04/2004 - 06/2002
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2020 - 05/2002
3LigandsIBA
06/2019 - 01/2008
3Drug CombinationsIBA
01/2019 - 03/2012
3HDL LipoproteinsIBA
02/2017 - 01/2015
3ErbB Receptors (EGF Receptor)IBA
02/2017 - 01/2011
3proto-oncogene proteins pimIBA
05/2016 - 02/2012
3Sorafenib (BAY 43-9006)FDA Link
01/2016 - 09/2012
3Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2016 - 01/2011
3Dasatinib (BMS 354825)FDA Link
07/2015 - 09/2008
3MTOR InhibitorsIBA
05/2014 - 02/2004
3Angiogenesis InhibitorsIBA
07/2013 - 01/2002

Therapy/Procedure

108Therapeutics
09/2023 - 01/2002
26Drug Therapy (Chemotherapy)
11/2023 - 05/2002
14Immunotherapy
01/2019 - 12/2015
5Stem Cell Transplantation
01/2007 - 09/2002
3Salvage Therapy
01/2016 - 04/2003